SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026
WW

WWB

Windward Bio Group AG
NEUTRAL
Impact 5/10
Horizonimmediate Processed3d 14h ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

Monitor first-day trading volume and price stability; the $50 million Sanofi private placement provides a strategic backstop and potential partnership signal. Watch for pipeline updates and cash runway guidance in subsequent filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$28.50
T+0 close · Nov 12, 2026 · via day close
Latest settled
+5.40%
T+1 · $30.04
Vs SPY
+7.32%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $28.50entry
  2. T+1 · 16h ago +5.40%α +7.32% · $30.04
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Windward Bio Group priced its IPO of 10.29 million common shares at $17.00 per share, with a concurrent $50 million private placement to Sanofi. Gross proceeds from the IPO and private placement are expected to total $225 million. Shares begin trading on Nasdaq on November 13, 2026.

Key Financial Metrics

Deal Value
$225.0M

Key Facts

  • IPO of 10,294,117 common shares at $17.00 per share
  • Underwriters have 30-day option for up to 1,544,117 additional shares
  • Concurrent private placement of 1,532,691 common shares and pre-funded warrants for 1,408,485 shares to Sanofi for $50.0 million
  • Combined gross proceeds expected to be $225.0 million
  • Shares expected to begin trading on Nasdaq on November 13, 2026 under symbol WWB
  • Offering expected to close on November 16, 2026

Financial Impact

Gross proceeds of $225 million from IPO and concurrent private placement

dilutioncash

Risk Factors

  • Clinical-stage biotech with no approved products; high execution risk
  • Underwriters' option could add further dilution if exercised
  • IPO pricing at $17.00 may not hold in secondary trading

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402338

US Market Status

Market Closed · Opens Wed (10h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026